Why is Share Price Falling?, page-22

I just got this in an email ...Mon, 6 June at 9:32 am


Monday, 6 June 2022

SHL - SONIC HEALTHCARE LIMITED

Credit Suisse rates SHL as Outperform (1) - Credit Suisse lowers the Australian base business pathology revenue estimates for FY23 by -6%. Stronger covid volumes in Germany lead to limited change in earnings estimates for FY22, reduced by just -3%.

The broker reduces the target to $39 from $40 and retains an Outperform rating.

Target price is $39.00 Current Price is $35.64 Difference: $3.36 If SHL meets the Credit Suisse target it will return approximately 9% (excluding dividends, fees and charges). Current consensus price target is $39.23, suggesting upside of 10.1%(ex-dividends)The company's fiscal year ends in June.

Forecast for FY22:

Credit Suisse forecasts a full year FY22 dividend of 97.75 cents and EPS of 301.00 cents . At the last closing share price the estimated dividend yield is 2.74%. At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 11.84. How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 311.3, implying annual growth of 13.0%. Current consensus DPS estimate is 99.4, implying a prospective dividend yield of 2.8%. Current consensus EPS estimate suggests the PER is 11.4.

Forecast for FY23:

Credit Suisse forecasts a full year FY23 dividend of 102.64 cents and EPS of 180.00 cents . At the last closing share price the estimated dividend yield is 2.88%. At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.80. How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 180.6, implying annual growth of -42.0%. Current consensus DPS estimate is 107.6, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 19.7.

Market Sentiment: 0.4All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources